Edition:
United Kingdom

Correvio Pharma Corp (CORV.OQ)

CORV.OQ on NASDAQ Stock Exchange Capital Market

2.44USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$2.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,928
52-wk High
$5.23
52-wk Low
$1.95

Latest Key Developments (Source: Significant Developments)

Correvio Announces At The Market Offering
Thursday, 14 Mar 2019 

March 14 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES AT THE MARKET OFFERING.CORREVIO PHARMA CORP - ENTERED INTO AT MARKET SALES ISSUANCE AGREEMENT DATED MARCH 13, 2019 WITH CANTOR FITZGERALD & CO..CORREVIO PHARMA CORP - UNDER AGREEMENT, CO MAY SELL COMMON SHARES OF UP TO $50 MILLION, SUBJECT TO LIMIT OF $12 MILLION UNDER ATM PROSPECTUS SUPPLEMENT.CORREVIO PHARMA - PLANS TO USE NET PROCEEDS FOR PREPARATIONS FOR FUTURE PRODUCT LAUNCHES, INCLUDING EXPECTED RESUBMISSION OF AN NDA FOR BRINAVESS.  Full Article

Correvio Pharma Reports Q4 Loss Per Share Of $0.18
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Correvio Pharma Corp ::CORREVIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.COMPANY ON TRACK TO RESUBMIT BRINAVESS NDA IN Q2 2019.Q4 LOSS PER SHARE $0.18.Q4 REVENUE $8.9 MILLION VERSUS $7.0 MILLION.CORREVIO PHARMA - MARK H.N. CORRIGAN HAS BEEN NAMED CORREVIO'S NEXT CHIEF EXECUTIVE OFFICER, EFFECTIVE MARCH 14, 2019.CORREVIO PHARMA - JUSTIN RENZ, CHIEF FINANCIAL OFFICER OF CORREVIO, ASSUMED THE RESPONSIBILITIES OF PRESIDENT.  Full Article

Correvio Announces Amendment To Term Loan With Crg-Managed Funds
Monday, 11 Mar 2019 

March 11 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES AMENDMENT TO TERM LOAN WITH CRG-MANAGED FUNDS.CORREVIO PHARMA CORP - AMENDMENT PROVIDES FOR UP TO AN ADDITIONAL $10 MILLION IN DEBT FUNDING.CORREVIO PHARMA CORP - REMAIN ON TRACK TO RESUBMIT BRINAVESS NDA DURING Q2 OF 2019.  Full Article

Correvio Pharma Corp - Chief Financial Officer, Justin Renz, Appointed President
Wednesday, 2 Jan 2019 

Correvio Pharma Corp ::CORREVIO ANNOUNCES CHIEF EXECUTIVE OFFICER SUCCESSION PLAN AND OTHER BOARD AND EXECUTIVE CHANGES.CORREVIO PHARMA CORP - CHIEF FINANCIAL OFFICER, JUSTIN RENZ, APPOINTED PRESIDENT.CORREVIO PHARMA CORP - VANDA DE CIAN, MD, TO JOIN BOARD OF DIRECTORS.CORREVIO PHARMA CORP - HUNTER TO REMAIN A MEMBER OF BOARD OF DIRECTORS.CORREVIO PHARMA CORP - MARK H.N. CORRIGAN, MD TO SUCCEED WILLIAM HUNTER, MD AS CHIEF EXECUTIVE OFFICER BY END OF Q1 2019.CORREVIO PHARMA CORP - DE CIAN WILL SERVE AS A MEMBER OF NOMINATING, GOVERNANCE AND COMPENSATION COMMITTEES.CORREVIO PHARMA CORP - HUNTER WILL TRANSITION OUT OF HIS CURRENT ROLE BY END OF Q1 OF 2019.  Full Article

Correvio Announces Brinavess Eligibility For Patent Extension
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES BRINAVESS ELIGIBILITY FOR PATENT EXTENSION.CORREVIO PHARMA - RECEIVED INDEPENDENT REGULATORY AND LEGAL OPINIONS THAT BRINAVESS MAY QUALIFY FOR UP TO 5-YEAR PATENT EXTENSION FROM USPTO.CORREVIO PHARMA CORP - WILL BE RESUBMITTING A NEW DRUG APPLICATION (NDA) FOR BRINAVESS TO FDA DURING Q2 OF 2019.  Full Article

Correvio Announces Intention To Re-File Brinavess NDA In Q2 2019
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES INTENTION TO RE-FILE BRINAVESS NDA IN SECOND QUARTER 2019.CORREVIO PHARMA CORP - PLANS TO RESUBMIT BRINAVESS (VERNAKALANT HYDROCHLORIDE, IV) NEW DRUG APPLICATION (NDA) DURING Q2 OF 2019.CORREVIO PHARMA CORP - NO ADDITIONAL STUDIES REQUIRED FOR RESUBMISSION.  Full Article

Correvio Q1 Loss Per Share $0.24
Tuesday, 15 May 2018 

May 15 (Reuters) - Cardiome Pharma Corp ::CORREVIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $6.5 MILLION VERSUS I/B/E/S VIEW $5.9 MILLION.Q1 LOSS PER SHARE $0.24.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CORREVIO PHARMA CORP - AT MARCH 31, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF $13.6 MILLION.  Full Article

Cardiome Announces Amendment To Term Loan Agreement With CRG Managed Funds
Friday, 6 Apr 2018 

April 6 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES AMENDMENT TO TERM LOAN AGREEMENT WITH CRG-MANAGED FUNDS.ENTERED INTO FIRST AMENDING AGREEMENT TO ITS MAY 11, 2017 AMENDED & RESTATED TERM LOAN AGREEMENT WITH CRG SERVICING LLC MANAGED FUNDS.CRG HAS WAIVED ITS RIGHT TO RECEIVE PAYMENT OF CERTAIN CASH COMPENSATION OF UP TO $6 MILLION DOLLARS.IN CONSIDERATION FOR ENTERING AMENDED AGREEMENT, CRG RECEIVED 800,000 COMMON SHARE PURCHASE WARRANTS WITH $2.50 EXERCISE PRICE.  Full Article

Cardiome Announces Expanded Label For Aggrastat In China
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN.CARDIOME PHARMA - AGGRASTAT EXPANDED LABEL NOW INCLUDE PATIENTS WITH STEMI WHO ARE INTENDED FOR PRIMARY PERCUTANEOUS CORONARY INTERVENTION.CARDIOME PHARMA - CHINESE CENTER FOR DRUG EVALUATION ALSO APPROVED AGGRASTAT HIGH DOSE BOLUS REGIMEN TO BE USED ON BOTH INDICATED PATIENT POPULATIONS IN STUDY.  Full Article

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA.CARDIOME PHARMA CORP - AFFILIATE CORREVIO HAS ENTERED INTO AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WITH ZAO FIRMA EUROSERVICE.CARDIOME PHARMA - AS PER LICENSE AGREEMENT, ZAO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS FOR AGGRASTAT FROM RUSSIA'S MINISTRY OF HEALTH.CARDIOME PHARMA CORP - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article